Trial reportHuman vaccines & immunotherapeutics2020
Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in HIV-infected adults in the era of highly active antiretroviral therapy: analysis stratified by CD4 T-cell count.
Trial report in Human vaccines & immunotherapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 18 citations in OpenAlex.
- Long-term Immunogenicity of the 13-valent Pneumococcal Conjugate Vaccine during Adjuvant Chemotherapy in Patients with Gastric and Colorectal Cancer: A 5-Year Follow-up of a Randomized Controlled Trial.Cancer research and treatment · 2026Trial
- Inadequate immune response to inactivated COVID-19 vaccine among older people living with HIV: a prospective cohort study.Journal of virology · 2025Trial
- Challenges in the Vaccination of HIV-Infected Individuals.Vaccines · 2025Review
- Article
- Association of Insomnia, Sleep Quality, and Sleep Duration With Risk of Physical Frailty in Middle-aged and Older People With HIV.Open forum infectious diseases · 2023Article
- Failure to seroconvert after three doses of inactivated COVID-19 vaccines in a patient co-infected with HBV and HIV: A case report.Human vaccines & immunotherapeutics · 2022Article
- Immune response and safety to inactivated COVID-19 vaccine: a comparison between people living with HIV and HIV-naive individuals.AIDS research and therapy · 2022Article
- Safety and antibody response to the first dose of severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine in persons with HIV.AIDS (London, England) · 2021Article
- Pneumococcal endocarditis involving the pulmonic valve in a patient with HIV.Proceedings (Baylor University. Medical Center) · 2021Article
- Vaccine responses in ageing and chronic viral infection.Oxford open immunology · 2021Review
- Single-Dose 13-Valent Conjugate Pneumococcal Vaccine in People Living With HIV - Immunological Response and Protection.Frontiers in immunology · 2021Article
- Immunogenicity of pneumococcal vaccination in HIV infected individuals: A systematic review and meta-analysis.EClinicalMedicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
HIV-infected patients are 30- to 100-fold more susceptible to invasive pneumococcal diseases than are healthy adults. Pneumococcal vaccination may be the best way to decrease the large pneumococcal disease burden, but the optimal timing of vaccination is still unclear. In this study, HIV-infected subjects aged ≥18 years were recruited and divided into 2 age-matched groups: group 1 (subjects with CD4 T-cell count ≥350 cells/µL) and group 2 (CD4 T-cell count <350 cells/µL). Multiplex opsonophagocytic killing assay was used to compare immunogenicity after immunization with 13-valent pneumococcal conjugate vaccine (PCV13). Among 70 subjects, 67 (group 1, N = 34; group 2, N = 33) were available for the assessment of immunogenicity and safety. With respect to the post-vaccination geometric mean titer (GMT) ratios, the non-inferiority criteria were not met. Post-vaccination GMTs were significantly lower in group 2 compared to group 1 for all 4 pneumococcal serotypes (5, 6B, 18C, and 19A) tested. PCV13 was safe and well tolerated in HIV-infected patients irrespective of immune status. In conclusion, PCV13 showed significantly inferior immunogenicity among HIV-infected patients with CD4 T-cell count <350 cells/µL compared to those with a higher CD4 T-cell count.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.